Ayça Gökçen Değirmenci Saltürk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ayça Gökçen Değirmenci Saltürk has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Fatih Güzelbulut
Department of Gastroenterology, Faculty of Medicine Ege University, Izmir, Turkiye
2 shared publications - Özgür Bahadır
Istanbul Medeniyet University
2 shared publications - Büşra Ünal
Department of Gastroenterology, Umraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey; 3GLAB (Genomic Laboratory), Umraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
1 shared publication - Cuneyt Salturk
Department of Chest Diseases, Medipol University Faculty of Medicine, İstanbul, Türkiye
1 shared publication - Emine Kanatsız
Department of Gastroenterology, Umraniye Training and Research Hospital, Istanbul, Turkey
1 shared publication - Gupse Adali
Department of Gastroenterology, University of Health Sciences, Istanbul Umraniye Training and Research Hospital, Istanbul, Turkiye
1 shared publication
Latest Publications
- Open Access
- 1 January 2022
- Published by Kare Publishing in Hepatology Forum
- Vol. 3 (1) , 11-15
Changes in the clinical characteristics of chronic hepatitis B patients at the initiation of treatment over a 15-year period
Background and Aim: This study aimed to evaluate the changes in the clinical characteristics of chronic Hepatitis B (CHB) patients at the initiation of treatment over a 15-years period. Materials and Methods: The study included 659 treatment-naive CHB patients who started receiving nucleos(t)ide analogs between January 2006 and December 2020. The patients included in the study were divided into three groups of five years each, according to the start date of treatment. Results: The mean age was 46.2±14.5 years and 445 (67.5%) were male. Two hundred and five (31.1%) patients had cirrhosis. Hepatocellular carcinoma (HCC) developed in forty-one patients (6.2%). Compared to patients in Group 1, Group 2 were younger and had lower decompensated cirrhosis, HCC and ascites, had higher Child A cirrhosis (all p
- 1 January 2022
- Published by Kare Publishing in Hepatology Forum
- Vol. 3 (1) , 11-15
Open AccessChanges in the clinical characteristics of chronic hepatitis B patients at the initiation of treatment over a 15-year period
Background and Aim: This study aimed to evaluate the changes in the clinical characteristics of chronic Hepatitis B (CHB) patients at the initiation of treatment over a 15-years period. Materials and Methods: The study included 659 treatment-naive CHB patients who started receiving nucleos(t)ide analogs between January 2006 and December 2020. The patients included in the study were divided into three groups of five years each, according to the start date of treatment. Results: The mean age was 46.2±14.5 years and 445 (67.5%) were male. Two hundred and five (31.1%) patients had cirrhosis. Hepatocellular carcinoma (HCC) developed in forty-one patients (6.2%). Compared to patients in Group 1, Group 2 were younger and had lower decompensated cirrhosis, HCC and ascites, had higher Child A cirrhosis (all p
- 1 January 2021
- Published by Kare Publishing in Hepatology Forum
- Vol. 2 (3) , 91-96
Are nucleos(t)ide analogs effective against severe outcomes in COVID-19 and hepatitis B virus coinfection?
Background and Aims: The impact of chronic hepatitis B virus (HBV) infection and nucleos(t)ide analogs (NUCs) treatment on disease severity and clinical outcomes in patients 2 with COVID-19 is unknown. The aim was to determine whether HBV infection and the use of NUCs impact mortality in patients with COVID-19. Materials and Methods: We conducted a retrospective study of 231 adult patients (77 with COVID-19 and HBV coinfection) with a laboratory-confirmed diagnosis of COVID-19. Univariate and binary logistic regression analyses were performed to evaluate the risk factors for mortality from COVID-19. Results: Patients with COVID-19 and HBV coinfection had a similar rate of mortality as those without HBV coinfection (7.8% vs 9.7%, p=0.627). Cardiovascular disease (OR 8.22; 1.52-44.2, p=0.014) and high basal AST level (OR 7.94; 1.81-34.8, p=0.006) were independent predictors of mortality from COVID-19. In the COVID-19 and HBV coinfection group, patients who died had significantly higher median levels of HBV DNA than patients who survived (378 IU/mL vs 0 IU/mL, p=0.048). Thirty (39%) patients with HBV coinfection were receiving NUC treatment, and none of these patients died. Conclusion: HBV infection was not associated with mortality in patients with COVID-19, and NUCs for HBV infection might have an antiviral effect on SARS-CoV-2 infection.
- 1 January 2021
- Published by Kare Publishing in Hepatology Forum
- Vol. 2 (3) , 91-96
Are nucleos(t)ide analogs effective against severe outcomes in COVID-19 and hepatitis B virus coinfection?
Background and Aims: The impact of chronic hepatitis B virus (HBV) infection and nucleos(t)ide analogs (NUCs) treatment on disease severity and clinical outcomes in patients 2 with COVID-19 is unknown. The aim was to determine whether HBV infection and the use of NUCs impact mortality in patients with COVID-19. Materials and Methods: We conducted a retrospective study of 231 adult patients (77 with COVID-19 and HBV coinfection) with a laboratory-confirmed diagnosis of COVID-19. Univariate and binary logistic regression analyses were performed to evaluate the risk factors for mortality from COVID-19. Results: Patients with COVID-19 and HBV coinfection had a similar rate of mortality as those without HBV coinfection (7.8% vs 9.7%, p=0.627). Cardiovascular disease (OR 8.22; 1.52-44.2, p=0.014) and high basal AST level (OR 7.94; 1.81-34.8, p=0.006) were independent predictors of mortality from COVID-19. In the COVID-19 and HBV coinfection group, patients who died had significantly higher median levels of HBV DNA than patients who survived (378 IU/mL vs 0 IU/mL, p=0.048). Thirty (39%) patients with HBV coinfection were receiving NUC treatment, and none of these patients died. Conclusion: HBV infection was not associated with mortality in patients with COVID-19, and NUCs for HBV infection might have an antiviral effect on SARS-CoV-2 infection.
- 30 December 2020
- Published by Galenos Yayinevi in Viral Hepatitis Journal
- Vol. 26 (3) , 119-123
Influence of Sustained Virological Response on APRI in Chronic Hepatitis C: is APRI a Marker of Only the Stage of Fibrosis?
- 30 December 2020
- Published by Galenos Yayinevi in Viral Hepatitis Journal
- Vol. 26 (3) , 119-123
Influence of Sustained Virological Response on APRI in Chronic Hepatitis C: is APRI a Marker of Only the Stage of Fibrosis?